Industry News

Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Was Associated with Improved Fat and Nutrient Absorption

05/06/2022

Preclinical data published in Journal of Clinical Nutrition highlight potential applications of ALC-078 cartridge in short bowel syndrome nutrition management Excerpt from the Press Release: NEWTON, Mass. , April 27, 2022 /PRNewswire/ — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced publication of preclinical data from the company’s development…

Read More

Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

05/06/2022

Based on positive feedback provided by FDA on key clinical design details Jasper plans to initiate registrational studies in AML and MDS patients Excerpt from the Press Release: REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc., (NASDAQ: JSPR) a biotechnology company focused on hematopoietic stem cell therapies, today announced that after…

Read More

Pyrukynd ushers in new era for rare cellular metabolic disease

05/06/2022

The approval of the first oral pill to treat a rare anemia heralds the arrival of a new class of agents that could shake up enzyme replacement therapies for metabolic disease. Excerpt from the Press Release: The US approval in February of Agios Pharmaceuticals’ Pyrukynd (mitapivat) for pyruvate kinase deficiency (PKD) is a first on…

Read More

VITRAC Therapeutics Initiates a Phase 1/2 Clinical Trial with the Aurora Kinase A inhibitor VIC-1911 in GVHD Prophylaxis

05/05/2022

Excerpt from the Press Release: VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1/2 clinical trial of VIC-1911 in combination with sirolimus and post-transplant cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis in myeloablative allogeneic stem cell transplantation. VIC-1911 is an oral selective Aurora kinase A inhibitor (AURKA). The trial is being carried out at the University…

Read More

Virpax Successfully Completes Initial Preclinical Studies for VRP324

05/05/2022

-Nasal CBD Candidate to Manage Seizures Associated with Epilepsy in Children and Adults- Excerpt from the Press Release: Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, CNS disorders and anti-viral indications, reported preclinical pharmacokinetics (PK) results for VRP324 (MET-CBD), a nose-to-brain delivery platform for CBD…

Read More

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

05/05/2022

PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm Achieved clinical proof-of-concept and validation for oral, gut-restricted approach for ulcerative colitis via blockade of the alpha-4-beta-7-integrin pathway  Plans underway for…

Read More

Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer

05/04/2022

Excerpt from the Press Release: Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the selection of Ambrx’s antibody drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2…

Read More

Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

05/04/2022

– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile– Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups– Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic…

Read More

EpicentRx “BETA-PRIME” Phase 1 Study Progresses After Demonstrating Good Safety and Tolerability

05/02/2022

Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer Excerpt from the Press Release: TORREY PINES, Calif., April 21, 2022 /PRNewswire/ — EpicentRx Inc., a leading-edge immunotherapy company using groundbreaking science to treat cancer and multiple inflammatory-driven diseases, today announced the initiation of the…

Read More

MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

05/02/2022

Excerpt from the Press Release: LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) animal model was…

Read More